

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 61679

**Title:** AC connects COVID-19 with cancer and cancer immunotherapy

**Reviewer's code:** 03522824

**Position:** Peer Reviewer

**Academic degree:** MBBS, MBChB, MD, MSc, PhD

**Professional title:** Assistant Professor

**Reviewer's Country/Territory:** Saudi Arabia

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-12-21

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-12-21 06:11

**Reviewer performed review:** 2020-12-29 12:01

**Review time:** 8 Days and 5 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

This letter is dealing with interesting research and clinical point especially nowadays with the Covid-19 epidemic, minor comments are there: - The abbreviation should mention in full words for the first time e.g. PD-L1. - Based on the author hypothesis, any compound with potential ACE 2 inhibition action should be avoided in cancer patients or cancer patient with Covid-19 ... it should be included as a conclusion in the abstract section